CRISPR Therapeutics AG (NASDAQ:CRSP) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 5:15 PM ET
Company Participants
Samarth Kulkarni – Chief Executive Officer and Chairman
Conference Call Participants
Fanchen Zhou – JPMorgan
Fanchen Zhou
Good afternoon, everyone. Thank you for coming here. Welcome to the 43rd Annual JPMorgan Healthcare Conference. My name is Fanchen Zhou. I’m an associate within the JPMorgan Healthcare Group. Today, it is my pleasure to introduce CRISPR Therapeutics.
With us today, we have Dr. Sam Kulkarni from CRISPR. The presentation will be in the format of 20 minutes of presentation followed by a 20 minute of Q&A.
With that, I will yield the stage to Dr. Sam.
Samarth Kulkarni
Thank you very much, and thank you for having us here, to describe the journey of our company, CRISPR Therapeutics, and the outlook going forward in what could be one of the most consequential years in the journey of our company.
Before I jump in, I will be making forward-looking statements, and I encourage you to go to our website for a full risk — list of risk factors. 1, 5, 10 is an easy way to encapsulate what we’ve accomplished over the last decade at CRISPR. We have one approved therapy in CASGEVY, which I’ll talk more about, based on the Nobel Prize-winning CRISPR/Cas9 technology.
We have five programs in the clinic across different disease areas, including oncology, autoimmune, cardiovascular medicines, and rare diseases. And we have a rich pipeline beyond that in 10 preclinical programs, which are all very promising. Our business is divided into four franchises. The one of the franchises that’s core is hemoglobinopathies or heme as we call it.
This is where we have our approved drug, CASGEVY, which is partnered with Vertex, and it’s a remarkable medicine for patients suffering from sickle cell
